IAVI (International AIDS Vaccine Initiative) has begun screening tests for inclusion in a study called Effie G003 At centers in Rwanda and South Africa. Moderna’s vaccine contains HIV-specific antigens that were already tested in the first phase of research last year.
Hopefully, the mRNA vaccine will prove it Effective against SARS-CoV-2Where traditional immunoprotective techniques to combat HIV have failed.
One of the candidates for the vaccine – mRNA-1644 Already demonstrated its potential in a previous phase 1 study (IAVI G001) conducted in the USA. symbols An antigen called eOD-GT8 60mer It motivates the goal Immune response to B lymphocytes in 97% Vaccine recipients.
According to the current state of knowledge, activation of B cells should lead to induction broadly neutralizing antibody (bnAb)It is widely believed to be the target of an effective HIV vaccine. self-immunization with eOD-GT8 60mer It is almost certainly not enough.
Scientists think about the application combinations of vaccines that target various HIV immunity, Like Core-g28v2 60mer to further enhance the immune response against HIV and improve protection against the pathogen. Earlier this year, the first healthy volunteers received mRNA-1644 in the second phase of the study (IAVI G002), which was funded in part by the Bill & Melinda Gates Foundation.
In IAVI G003 18 healthy adult volunteers without HIV will participatewho will be receiving two doses of eOD-GT8 60mer. They will be followed up for six months to study the safety and effectiveness of the vaccine. This study will be the first in Africa to evaluate the immunogenicity of HIV delivered in the form of mRNA.
More than an HIV vaccine Scientists have been working for more than 30 years. The virus’ tendency to mutate means that conventional vaccines are ineffective — at least four vaccine candidates have failed in the full cycle of clinical trials (including the high hopes of Johnson & Johnson).
Ad26.Mos4. HIV Vaccineusing the same adenoviral technology as J&J’s SARS-CoV-2 vaccine and targeting four HIV antigens was shown to be safe, but did not achieve its goal of Reduce HIV transmission by 50% The HVTN 702 study of two co-administered HIV vaccine candidates developed by Sanofi Pasteur and GlaxoSmithKline jointly with GSK adjuvant MF59 last year was also halted due to lack of efficacy.
“Infuriatingly humble musicaholic. Problem solver. Reader. Hardcore writer. Alcohol evangelist.”